Evaluating the SFP 10-14 in Europe

Alongside the ongoing evaluation of the adapted SFP10-14 in the UK, Diageo is providing support for the adaptation and testing of SFP10-14 in other European countries co-ordinated by researchers at Oxford Brookes University. In Spain researchers from the University of Oviedo are working together with the Spanish Psychological Association sponsored by both the Spanish National Plan for Drugs and Diageo Spain. Information on other countries will be added to this website as new projects are confirmed.

Each new adaptation and evaluation will follow the guidance for developing and testing complex health and social care interventions from the U.K. Medical Research Council. The different phases of evaluating a complex intervention, such as the SFP10-14, are shown in this diagram:

Initially, an intervention is developed based on relevant theory. The SFP10-14 was developed originally by Professor Virginia Molgaard from earlier version of the SFP10-14 originally developed by Dr. Karol Kumpfer and is based on the biopsychosocial theoretical model. Adaptations of the original SFP10-14 are consistent with this theoretical approach.

At Phase I of the SFP10-14 adaptation project the original programme material is translated and adapted for use in a different cultural context and language. The revised materials are discussed with a range of stakeholders using nominal and focus groups to ensure an appropriate, reliable translation and adaptation. This Phase should take no more than 6-12 months.

At Phase II the adapted materials are piloted and tested in an exploratory trial in 2-3 different sites. Young people and their parents are allocated to receive the new SFP10-14 or to a control group, and are followed up for a short period (usually 6 months). This Phase should take no more than 12-18 months.

For further details of the Phase I and Phase II steps see the information of the adaptation of the SFP 10-14 in the UK.

At Phase III the new SFP10-14 material is evaluated in a large randomised controlled trial to test the effectiveness of the prevention programme compared with a control group who do not receive the SFP10-14, and also to compare the results with the original results from Iowa in the United States. This Phase will take several years, with follow-ups carried out every year. This Phase will also incorporate a health economic assessment to examine the cost-effectiveness of the SFP10-14 in different settings.

Phase IV assumes that the effectiveness of the SFP10-14 has been demonstrated at Phase III and that a wider implementation of the SFP10-14 has taken place within a particular country. Once the programme is implemented more widely there is an opportunity to follow up the participants to see if the programme is still performing as expected, or as suggested from the Phase III results.